Placebo + RO5093151

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Conditions

Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Trial Timeline

Apr 1, 2011 → Mar 1, 2012

NCT ID

NCT01277094

About Placebo + RO5093151

Placebo + RO5093151 is a phase 1 stage product being developed by Roche for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT01277094. Target conditions include Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD.

What happened to similar drugs?

6 of 12 similar drugs in Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD were approved

Approved (6) Terminated (3) Active (4)

✅Orlistat (Xenical)RocheApproved

✅Xenical, Pegasys, CopegusRocheApproved

✅atorvastatin + Vitamin EPfizerApproved

✅Testosterone Undecanoate + PlaceboBayerApproved

✅Clinolipid + IntralipidBaxterApproved

🔄GODEX + PlaceboCelltrionPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01493271	Phase 2	Completed	Dec 1, 2011	Nov 1, 2012	Hypertension, Glaucoma, Open-Angle
NCT01277094	Phase 1	Completed	Apr 1, 2011	Mar 1, 2012	Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

Competing Products

20 competing products in Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD

See all competitors

Product	Company	Stage	Hype Score
Lanifibranor	Inventiva	Phase 2	29
Low Dose REN001 + High Dose REN001	OnKure Therapeutics	Phase 1	19
GODEX + Placebo	Celltrion	Phase 3	47
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo	AstraZeneca	Phase 2	35
AZ compound	AstraZeneca	Phase 2	27
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo	AstraZeneca	Phase 2	35
AZD7503 Intervention	AstraZeneca	Phase 1	29
metformin	Merck	Phase 2/3	34
Efinopegdutide + Semaglutide + Placebo	Merck	Phase 2	35
MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride	Merck	Phase 1	29
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL	Merck	Phase 2	35
LYS006 + Tropifexor	Novartis	Phase 2	27
LJN452	Novartis	Phase 1	29
LCQ908 + placebo	Novartis	Phase 2	35
Orlistat (Xenical)	Roche	Approved	43
Xenical, Pegasys, Copegus	Roche	Approved	43
AMG 609 + Placebo	Amgen	Phase 1	29
Glucagon	Novo Nordisk	Pre-clinical	26
Blood samples	Novo Nordisk	Pre-clinical	18
NNC0194-0499 + NNC0194-0499 + NC0194-0499	Novo Nordisk	Phase 1	29